Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
Price analytics
Returns
1 day
-1.8%
1 week
-8.5%
1 month
12.5%
3 months
45.9%
6 months
31.7%
1 year
74.2%
3 years
125.0%
Risk
Volatility (1y ann.)
75.1%
Beta vs ASX 200
1.04
Sharpe (1y)
1.06
VaR 95% (1-day)
-6.9%
Max drawdown (1y)
-55.7%
Off 1-year high
-22.9%
Technicals
RSI(14)
40
vs 50DMA
8.9%
vs 200DMA
21.7%
Trend
Golden cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value62.5
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
0
Price / Sales
0
Growth100.0
Revenue growth (1y)
100
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health68.7
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
100
Debt / Equity
99
Quality (Profitability & Cash Flow)0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income—
No meaningful dividend — pillar excluded from the overall score.
Momentum90.2
6-month return vs ASX 200
100
Price vs 200-day average
100
Price vs 50-day average
94
Position in 52-week range
59
Hover a row's info icon for the exact rule. Bounds and weights are configurable in
the Django admin (Scoring configuration).